CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status

A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways

(2009) Jung Jin Hwang et al.   ANTI-CANCER DRUGS

Histone deacetylase inhibitor induced modulation of anti-estrogen therapy

(2009) Scott Thomas et al.   CANCER LETTERS

Isoform-specific histone deacetylase inhibitors: The next step?

(2009) Sriram Balasubramanian et al.   CANCER LETTERS

Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma

(2009) Takashi Watanabe et al.   CANCER SCIENCE

Histone Deacetylase Inhibitors

(2009) Xujun Ma et al.   DRUGS

Valproic acid restores ERα and antiestrogen sensitivity to ERα-negative breast cancer cells

(2009) N. Fortunati et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

HDAC family: What are the cancer relevant targets?

(2008) Olaf Witt et al.   CANCER LETTERS

Statins Increase p21 through Inhibition of Histone Deacetylase Activity and Release of Promoter-Associated HDAC1/2

(2008) Y.-C. Lin et al.   CANCER RESEARCH

Inhibition of Histone Deacetylases Promotes Ubiquitin-Dependent Proteasomal Degradation of DNA Methyltransferase 1 in Human Breast Cancer Cells

(2008) Q. Zhou et al.   MOLECULAR CANCER RESEARCH

Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells

(2007) Nicoletta Fortunati et al.   CANCER LETTERS